Clinical data collection and measurement of serum biomarkers
Demographic and all clinical features including medications were
collected from medical records. Measurements of heart rate, systolic and
diastolic blood pressures at least 20 minutes of relaxing and body mass
index were initially performed in all study participants. Serum baseline
tryptase levels, full blood count, serum glucose level, triglyceride,
low density lipoprotein (LDL) cholesterol, high density lipoprotein
(HDL) cholesterol, erythrocyte sedimentation rate (ESR) and high
sensitive c-reactive protein (hsCRP) were measured in all study
participants after at least 8 hours of fasting. In patients with
recurrent anaphylaxis episodes, serum tryptase levels were measured at
least 2 weeks after the last attack. Ten ml peripheral venous blood
samples were collected for the measurement of endocan, ET-1, IL-6, VEGF,
TNF-α levels in both groups and centrifuged at 4000 rpm for 10 minutes
and then stored at-80C0 until the day of measurement.
Serum endocan, ET-1, VEGF, TNF-α and IL-6 levels were measured by the
enzyme-linked immunosorbent assay (ELISA) (IL-6 ELISA Kit and TNF- α
ELISA Kit: Diaclone SAS, Besancon, France; Endocan ELISA Kit, ET-1 ELISA
Kit and VEGF ELISA Kit: Abbkine Scientific, Wuhan, China) and serum
tryptase by ELISA Immunoassay (EIA) (fluoroenzyme immunoassay, Phadia,
Uppsala, Sweden). Serum biomarkers, FMD and CIMT measurements in the
patient group were evaluated before the start of management in order not
to cause any interference of certain drugs on study outcome.